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http://www.biomedcentral.com/1471-2407/12/353RESEARCH ARTICLE Open AccessHepatitis B virus X protein suppresses caveolin-1
expression in hepatocellular carcinoma by
regulating DNA methylation
Jun Yan1†, Qian Lu1†, Jiahong Dong2*, Xiaowu Li1*, Kuansheng Ma1 and Lei Cai1Abstract
Background: To understand the molecular mechanisms of caveolin-1 downregulation by hepatitis B virus X
protein (HBx).
Methods: The DNA methylation status of the caveolin-1 promoter was examined by nested methylation-specific
PCR of 33 hepatitis B virus (HBV)-infected hepatocellular carcinoma (HCC) samples. The SMMC-7721 hepatoma cell
line was transfected with a recombinant HBx adenoviral vector, and the effects of HBx protein on caveolin-1
expression and promoter methylation were examined and confirmed by sequencing. A reporter gene containing
the caveolin-1 promoter region was constructed, and the effects of HBx on the transcriptional activity of the
promoter were also studied.
Results: Methylation of the caveolin-1 promoter was detected in 84.8% (28/33) of HBV-infected HCC samples.
Expression of caveolin-1 was significantly downregulated (P = 0.022), and multiple CpG sites in the promoter region
of caveolin-1 were methylated in SMMC-7721 cells after HBx transfection. Transfected HBx significantly suppressed
caveolin-1 promoter activity (P = 0.001).
Conclusions: HBx protein induces methylation of the caveolin-1 promoter region and suppresses its expression.
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Hepatitis B virus (HBV) is one of the leading causes of
hepatocellular carcinoma (HCC). Among the four open
reading frames in the HBV genome (S, C, P and X), the
HBx protein is the most implicated in the pathogenesis of
HCC. HBx protein is involved in multiple steps of carcin-
oma development and activates several signal transduction
pathways that lead to transcriptional upregulation of a
number of genes including growth factor genes and onco-
genes. In addition, HBx promotes cell cycle progression,
inactivates negative growth regulators, such as p53, and
facilitates tumor invasion and metastasis [1-3].
Caveolin-1 is a candidate tumor suppressor gene [4,5].
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reproduction in any medium, provided the orsignificantly decreased in HBV-infected HCC tissues and
closely correlates with tumor progression. Although a
negative correlation between caveolin-1 and HBx expres-
sion was also found, it is unclear whether HBx leads to
caveolin-1 downregulation [6]. Because hypermethyla-
tion in promoter regions of tumor suppressor genes is
often induced by viral infection, and inactivation of
tumor suppressors is a major cause of carcinogenesis,
we hypothesized that HBx might regulate caveolin-1
expression by a similar mechanism.Methods
Materials
The SMMC-7221 hepatoma cell line was purchased from
the Cell Bank of the Chinese Academy of Sciences
(Shanghai, China) and confirmed as not infected with HBV.
Thirty-three HCC tissue samples were obtained from 29
male and 4 female patients between 2006 and 2007 at the
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42.3±10.6. Patients did not receive radiotherapy or chemo-
therapy before surgical removal of the affected liver. All
patients had chronic HBV infection, and HCC was con-
firmed by pathological studies. Healthy liver tissues were
obtained from donated livers during liver transplant-
ation surgery. This study met the requirements of the
Declaration of Helsinki, and was approved by the Re-
search Ethics Committee of the Southwest Hospital.
Informed consent was obtained from all participants.
Immunohistochemistry
Immunohistochemical staining was performed on 5 μm
tissue sections using a rabbit anti-human caveolin-1
polyclonal antibody (Santa Cruz Biotechnology, Japan).
For caveolin immunostaining, sections were treated with
3% H2O2 for 15 minutes, and then antigen retrieval was
performed by boiling in 0.01 M citrate buffer in a micro-
wave for 12 minutes. Sections were then immersed in
phosphate-buffered saline for 20 minutes, incubated for
20 minutes in a milk-peroxide blocking solution, and
then incubated with the primary antibody (1:500 dilu-
tion) overnight at 4°C. Incubated with the secondary
antibody (goat anti-rabbit antibody, Zhongshan Golden
Bridge Biotechnology, China) for 2 hours, and develop-
ment with diaminobenzidine Sections were counter-
stained with hematoxylin.
Cell culture and transient transfection
SMMC-7721 hepatoma cells were maintained in Dulbecco’s
modified eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS) (Hyclone, USA) at 37°C
with 5% CO2. Recombinant adenoviral vectors contai-
ning either the HBx gene (HBx-ayw subtype adenoviral
vector [7]; the original plasmid was kindly provided by
Dr. David Chan, University of Hong Kong) or control
green fluorescent portein (GFP) gene were used to in-
fect 80% confluent SMMC-7721 cells. To reduce the
cytotoxicity of adenovirus infection, the culture medium
was changed after 6–8 hours. GFP expression was con-
firmed by fluorescence microscopy after 48 hours post-
infection, and the transfection efficiency was approxi-
mately 80%. Cells were then harvested for the following
experiments.
Real-time PCR
Total RNA from SMMC-7721 hepatoma cells was
extracted by Trizol (Invitrogen, USA), and cDNA was
synthesized by reverse transcriptase (Cat#: DRR03s;
Takara, Dalian, China) according to the manufacturer’s
instructions. Caveolin-1 and HBx expression were exam-
ined by RT-PCR kits (DRR041s; Takara) using a thermocy-
cler (LightCycler; Roche, Switzerland). Primer sequences
were as follows: caveolin-1, forward 5′-AGA CGA GCTGAG CGA GAA-3′ and reverse 5′-GCA GAC AGC AAG
CGG TAA-3′; HBx, forward 5′-GCA CCT CTC TTT
ACG CGG ACT-3′ and reverse 5′-TAC AAA GAC CTT
TAA TCT AAT C-3′; β-actin, forward 5′-CGG GAA ATC
GTG CGT GAC-3′ and reverse 5′-TGG AAG GTG GAC
AGC GAG G-3′. cDNA from MHCC-97 L hepatoma cells
was used as a control for caveolin-1 analysis. cDNA from
HepG2 hepatoma cells transiently transfected with HBx
was used as a control for HBx analysis. Real-time PCR pro-
ducts were also examined by gel electrophoresis.Western blotting
SMMC-7721 cell lysates were prepared at 72 hours post-
transfection and quantified by the Bradford method.
Protein samples were examined by 10% SDS-PAGE ana-
lysis, transferred to PVDF membranes, blocked with 5%
milk and incubated with a primary mouse anti-HBx
monoclonal antibody (1:500 dilution)or a rabbit anti-
human caveolin-1 polyclonal antibody (1:500 dilution) at
4°C overnight. Samples were then incubated with a sec-
ondary goat anti-mouse or goat anti-rabbit IgG H+L
antibody at 37°C for 2 hours. Blots were developed by a
chemiluminescence kit (Pierce, USA). β-actin was used
as an internal reference.Nested methylation-specific PCR (n-MSP)
DNA methylation usually occurs in CpG islands in pro-
moter regions. We analyzed the promoter sequence of the
caveolin-1 gene (NCBI ID: AF019742) to determine
whether it contained CpG islands (http://ccnt.hsc.usc.edu/
cpgislands2/cpg.aspx). A typical CpG island sequence was
found in this region as shown in Figure 1A. Caveolin-1
MSP-specific PCR primers were designed as shown in [8,9]:
outside forward 5′-AGGATAGGGTAGGATTGTGG-3′
and outside reverse 5′-CATAAA ACATTCCTAACTTC
TCTTCACCTC-3′; methylated forward 5′-GGTATTTT




AAAAACAAAAAAC-3′. The location of the DNA frag-
ments is shown in Figure 1A. DNA from SMMC-7721
cells, healthy liver tissue, and HCC liver tissue was
extracted and treated with a DNA methylation conversion
kit (Zymo Research, Beijing). Nested PCR was performed
first with outside primers and a high GC-content PCR kit
(LA PCR Kit, Takara). First PCR products were diluted 30-
fold before being used as a secondary PCR template. Then,
methylation-specific and non-methylation PCR were per-
formed. PCR products were separated using gel electro-
phoresis. Healthy liver tissue DNA was used as an
unmethylated positive control and a methylated negative
control. Tissue DNA treated with CpG methylase (M.Sss I;
Figure 1 (See legend on next page.)
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Figure 1 HBx induces DNA methylation in the promoter region of the caveolin-1 gene. (A) There is a CpG island in the promoter region of
the caveolin-1 gene. Gene of Interest: The targeted gene that we studied. (B) DNA methylation status in HCC tissues was examined by n-MSP.
U: unmethylated PCR products, M: methylated PCR products. 1: healthy liver tissue, 2: M.Sss I-treated healthy liver tissue, 3–9: HCC liver tissues.
(C) DNA methylation status in SMMC-7721 cells was examined. 1: healthy liver tissue, 2: M.Sss I-treated healthy liver tissue, 3: mock-treated cells,
4: HBx-transfected cells. (D) Methylated CpG sites in the caveolin-1 promoter region were identified by sequencing. Black boxes represent newly
methylated CpG sites after HBx transfection. Red boxes represent de novo methylated CpG sites. U: Pmd-18 T-Cav-U, M: Pmd-18 T-Cav-M. (E) DNA
methylation status was examined in SMMC-7721 cells, 1: mock treatment, 2: (Mock-a) mock and 5′-Aza-2′-DC treatment, 3: HBx transfection,
4: (HBx-a) HBx transfection and 5′-Aza-2′-DC treatment. (F) Caveolin-1 mRNA was examined at 48 hours post-infection by RT-PCR, 1: mock
treatment, 2: HBx transfection, 3: HBx transfection and 5′-Aza-2′-DC treatment. (G) Caveolin-1 protein expression in SMMC-7721 cells was
examined at 48 hours post-infection by western blot. Mock: SMMC-7721 cells were transfected with an empty GFP recombinant adenoviral
vector. HBx: HBx transfection, HBx-a: HBx transfection and 5′-Aza-2′-DC treatment. (H) Transcriptional activity of the caveolin-1 promoter was
determined by a dual luciferase reporter assay. pGL3-Basic: empty vector, pGL3-Basic-Cavpro: recombinant pGL3-Basic containing the caveolin-1
promoter. (I) Expression of caveolin-1 in HCC and adjacent tissue with HBV infection, as determined by immunohistochemistry. A: adjacent non-
tumor tissue, B: HCC. (J) DNA methylation status in adjacent non-tumor tissue and HCC was examined by n-MSP. U: unmethylated PCR products,
M: methylated PCR products. 1: healthy liver tissue, 2: M.Sss I-treated healthy liver tissue, 3: adjacent non-tumor tissue, 4: HCC.
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an unmethylated negative control.Sequencing
To characterize CpG methylation sites in the promoter
region of the caveolin-1 gene, PCR products from con-
trol SMMC-7721 and HBx-transfected SMMC-7721
cells were ligated into a Pmd18-T plasmid (Takara) and
designated as Pmd-18 T-Cav-U and Pmd-18 T-Cav-M,
respectively. DNA sequences were analyzed by Invitro-
gen (Shanghai, China).5′-Aza-2′-DC treatment
SMMC-7721 hepatoma cells were seeded in 6-well
plates and 5′-Aza-2′-DC (Sigma, USA) was added to
wells. DNA, RNA, and protein were extracted after
72 hours to perform n-MSP, RT-PCR and western blot
analyses.Plasmid construction
The caveolin-1 promoter region (AF019742.1, NCBI
GenBank) was amplified from healthy liver tissue DNA.
The primers used were: forward primer, 5′-CGGGGT
ACCCTTTCCTCACAGCCAAGCACAT-3′ and reverse
primer, 5′-CCGCTCGAGTTTGGAGAGGCAGATAGC
AGAAG-3′. PCR products were separated by gel elec-
trophoresis, extracted and inserted into a Pmd-18-T
plasmid. DH10B competent cells were transformed with
recombinant plasmids. Transformed bacteria were cul-
tured, and plasmids were extracted using E.Z.N.A Plas-
mid Miniprep Kit (Omega Bio-tek US), Then, plasmids
were cleaved by Kpn and Xho restriction endonucleases
to confirm the insert. Finally, DNA fragments were
inserted into a pGL3-Basic plasmid (Promega, US)
and confirmed by restriction enzyme digestion and
sequencing.Dual-Luciferase reporter assay
A reporter plasmid containing the caveolin-1 promoter re-
gion (pGL3-Basic-Cavpro) was amplified, extracted and
purified. A pRL-TK vector (Promega, USA) was used as a
control. SMMC-7721 cells were seeded in 96-well plates.
After 24 hours, the luciferase transfection complex and re-
combinant adenoviral vector were added to the culture
medium. Some wells were also treated with 5′-Aza-2′-DC.
Culture medium was changed after 8 hours, and luciferase
activity was assessed after 48 hours using pGL3-Basic as a
control.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 soft-
ware. A T-test was used for comparison between two
groups, and one-way analysis of variance was used for
comparison between more than two groups. A value of
P < 0.05 was considered statistically significant.
Results
HBx downregulates caveolin-1 expression in SMMC-7721
cells
SMMC-7721 is a hepatoma cell line that is not infected
with HBV. We found that HBx was successfully
expressed following transfection into SMMC-7721 cells
(Figure 2A). Caveolin-1 was significantly decreased at
both mRNA and protein levels after Hbx transfection
(Figure 2B–D), indicating that HBx downregulated
caveolin-1 expression in SMMC-7721 hepatoma cells.
HBx induces methylation in the promoter region of the
caveolin-1 gene in SMMC-7721 cells
Using immunohistochemical staining to detect caveolin-
1 in HBV-positive HCC and adjacent normal tissues, we
found that the expression of caveolin-1 was decreased
significantly in HCC, compared with that in adjacent tis-
sues (Figure 1I). To examine whether there was DNA
methylation in the promoter region of the caveolin-1
Figure 2 HBx downregulates caveolin-1 expression in SMMC-7721 hepatoma cells. (A) HBx expression was examined by western blot
(48 hours post-infection). SMMC-7721 cells do not express endogenous HBx, while HBx was effectively produced after HBx transfection. (B, C)
Caveolin-1 mRNA expression in mock- and HBx-transfected cells was examined by real-time PCR. The grey value of the images was measured
with Quantity One 4.5. Caveolin-1 in HBx cells was significantly less than that in mock cells (P = 0.022) (examined at 48 hours post-infection).
(D) Caveolin-1 protein expression in HBx cells, examined by western blotting, was significantly less than that in mock cells.
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formed n-MSP analysis of 33 HCC samples. We found
that 84.8% (28/33) were positive for methylation,
whereas only 15.2% (5/33) did not show methylation
(Figure 1B), indicating that methylation in the promoter
region of caveolin-1 was prevalent among HBV-infected
HCC patients. However, between HCC and adjacent
non-tumor tissue in these specimens, we found that the
HCC tissue was positive for methylation, but it was
negative for methylation in the adjacent non-tumor tis-
sue in the same specimens (Figure 1J). We also exam-
ined the methylation status in SMMC-7721 hepatoma
cells and found that the caveolin-1 promoter was not
methylated in mock-treated cells, whereas HBx-
transfected cells were positive for both methylation and
non-methylation. This result indicated that methylationin the caveolin-1 promoter region was caused by HBx in
SMMC-7721 cells (Figure 1C). To identify CpG methy-
lation sites in the caveolin-1 promoter, we sequenced
unmethylated and methylated PCR products. The
unmethylated product (Pmd-18 T-Cav-U) corresponded
to the −411~−181 segment of the caveolin-1 promoter,
whereas the methylated product (Pmd-18 T-Cav-M) cor-
responded to the – 401~−191 segment of the caveolin-
1 promoter and contained 16 CpG sites. We found that
there was only one methylated CpG site in unmethylated
PCR products amplified from control SMMC-7721
cells, whereas there were 16 methylated CpG sties in
methylated PCR products amplified from HBx-
transfected SMMC-7721 cells, suggesting that HBx
induced methylation of the other 15 CpG sites in this re-
gion (Figure 1D). We also found that 5′-Aza-2′-DC
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caveolin-1 promoter (Figure 1E). Moreover, caveolin-1
was significantly increased at both the mRNA and pro-
tein levels after 5′-Aza-2′-DC treatment (Figure 1F–G).
Next, a dual-luciferase reporter assay was conducted to
examine the transcriptional activity of the caveolin-1
promoter. We found that exogenous HBx could signifi-
cantly downregulate caveolin-1 promoter activity
(P = 0.001), whereas 5′-Aza-2′-DC treatment inhibited
such an effect. This result indicated that HBx decreases
caveolin-1 expression by DNA methylation-mediated
suppression of the caveolin-1 promoter (Figure 1H).
Discussion
In tumor cells, hypermethylation of CpG islands in the
promoter regions of tumor suppressor genes often
results in transcriptional silencing. This event often cor-
relates with loss of protein expression, which is widely
recognized as a major contributing factor in tumorigen-
esis and malignancy. Hypermethylation of CpG islands
in several tumor suppressor genes, including p53, p16,
E-cadherin, Nm23, and MLH1, has been reported in sev-
eral types of malignant tumors [10-15].
Recent studies revealed that the caveolin-1 promoter re-
gion is hypermethylated in lung, breast, cervical and blad-
der cancers, as well as leukemia [8,9,16,17]. Hirasawa Y
et al. reported that 38% of HCC tissues show hypermethy-
lation in the promoter region of the caveolin-1 gene. In
their report, hypermethylation was also found in the hepa-
toma cell line Hep3B that is infected with HBV [18]. In
our current study, we found that most (84.8%, 28/33)
HBV-infected HCC tissues showed hypermethylation in
the promoter region of the caveolin-1 gene, indicating that
this epigenetic change is prevalent among patients with
HBV-related HCC. As a classic qualitative method for
DNA methylation, n-MSP is not accurate enough for
evaluating the level of DNA methylation. It would be bet-
ter to use Methylight assays to show the level of DNA
methylation and to correlate it to the level of expression
of caveolin-1 and HBx using quantitative assays for ex-
pression analysis such as qRT-PCR or Western blotting.
However, there was not a sufficient amount of HCC tis-
sues to perform such further experiments. So, the correl-
ation between DNA methylation and the expression of
corresponding mRNA and protein would be researched
using quantitative assays in future studies.
Many viral infections, including HBV, induce hyper-
methylation in the promoter regions of many tumor
suppressor genes, which results in transcriptional silen-
cing and loss of protein expression. Jung et al. reported
that HBx induces hypermethylation in the promoter re-
gion of E-Cadherin, which results in its suppression [19].
A negative correlation between HBx and caveolin-1 ex-
pression was found in our previous study based on acohort of patients with HBV-related HCC [6]. This ob-
servation suggests that a similar mechanism, in which
caveolin-1 is repressed by HBx-mediated DNA methyla-
tion, might exist. In fact, we found that transfection of
HBx significantly suppressed the transcriptional activity
of the caveolin-1 promoter and decreased caveolin-1 ex-
pression at the protein level. Next, we investigated the
DNA sequence of the caveolin-1 promoter to identify
CpG islands. We found that HBx methylated CpG sites
within the caveolin-1 promoter. Because 5′-Aza-2′-DC
inhibits methylation of CpG islands by inhibiting DNA
methyltransferase (DNMT) activity, we used 5′-Aza-
2′-DC to treat HBx-transfected SMMC-7721 cells. We
found that the promoter region of caveolin-1 was almost
completely unmethylated following treatment. Moreover,
the suppressive effect of HBx on caveolin-1 expression
was also completely abolished, indicating that HBx-
mediated DNA methylation is the leading cause of
caveolin-1 suppression.
Our previous study found that caveolin-1 expression is
significantly decreased in HCC. In addition, caveolin-1
expression inversely correlates with the tumor size, alpha
fetal protein level, vascular invasion, tumor number and
pathological TNM (pTNM) staging, which implied that
the expression of caveolin-1 gradually decreased with
HCC progression. MHCC-97 H and MHCC-97 L cells
are derived from parental MHCC-97 cells. MHCC-97 H
cells are more invasive and malignant, and express less
caveolin-1 than MHCC-97 L cells, which is consistent
with its possible role as a tumor suppressor [6]. Interest-
ingly, we recently found that overexpression of caveolin-
1 decreased tumor invasion and metastasis (unpublished
data), supporting the hypothesis that caveolin-1 sup-
presses tumorigenesis.Conclusions
HBV is one of the leading causes of HCC. For the first
time, we report that HBx induces hypermethylation of
the promoter region of the caveolin-1 gene, suppresses
its transcriptional activity, and decreases its expression.
Our results indicate that this epigenetic regulation of
caveolin-1 by HBx might play a major role in HCC
development.
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